15 research outputs found
Topological Susceptibility under Gradient Flow
We study the impact of the Gradient Flow on the topology in various models of
lattice field theory. The topological susceptibility is measured
directly, and by the slab method, which is based on the topological content of
sub-volumes ("slabs") and estimates even when the system remains
trapped in a fixed topological sector. The results obtained by both methods are
essentially consistent, but the impact of the Gradient Flow on the
characteristic quantity of the slab method seems to be different in 2-flavour
QCD and in the 2d O(3) model. In the latter model, we further address the
question whether or not the Gradient Flow leads to a finite continuum limit of
the topological susceptibility (rescaled by the correlation length squared,
). This ongoing study is based on direct measurements of in lattices, at .Comment: 8 pages, LaTex, 5 figures, talk presented at the 35th International
Symposium on Lattice Field Theory, June 18-24, 2017, Granada, Spai
Probabilistic sensitivity analysis (PSA) results.
(A) Cost-Effectiveness Acceptability Curves Comparing the Cost-effectiveness of Crizotinib Treatment with the ALK Rearrangement Testing (NGS and multiplex PCR) Versus Standard Chemotherapy, with PAP; (B) Scatter Plot of Monte Carlo Probabilistic Sensitivity Analysis, NGS vs. Control Strategy, with Patient Assistance Program (PAP); (C) Scatter Plot of Monte Carlo Probabilistic Sensitivity Analysis, Multiplex PCR vs. Control Strategy, with Patient Assistance Program (PAP). Blue line indicates NGS and yellow one is multiplex PCR, ALK: anaplastic lymphoma kinase; NGS: next-generation sequencing; PAP: patient assistance program; QALY: quality-adjusted life-year; PCR: polymerase chain reaction.</p
Summary of cost (US dollars) and outcome results in the base-case analysis.
Summary of cost (US dollars) and outcome results in the base-case analysis.</p
One-way sensitivity analyses for NGS panel tests and multiplex PCR versus control (with PAP).
(A) NGS vs. control; (B) multiplex PCR vs. control. NGS: next-generation sequencing; PAP: patient assistance program; QALY: quality-adjusted life-year.</p
Health utilities and disutilities of advanced NSCLC.
NSCLC: non-small-cell lung cancer; PFS: progression-free survival; OS: overall survival.</p
Additional file 1 of Dietary novel alkaline protease from Bacillus licheniformis improves broiler meat nutritional value and modulates intestinal microbiota and metabolites
Additional file 1: Fig. S1. Effects of novel protease feed on growth performance (A). Effects of novel protease feed on antioxidant capacity of breast muscle (B). a−c Different lowercase letters indicate significant difference between groups (P < 0.05)
Peripheral arterial occlusive disease: Global gene expression analyses suggest a major role for immune and inflammatory responses-2
a Venn diagram. B, C. Heatmap representation of commonly up-regulated genes (B) and commonly down-regulated genes (C) in overlapping genes, respectively. Samples are displayed in columns and genes in rows. Gene expression is represented as a color, normalized across each row, with brighter red for higher values and brighter green for lower values. Gene symbols are listed to the right. N (Normal control group), Int (intermediate lesions group), Ad (advanced lesions group).<p><b>Copyright information:</b></p><p>Taken from "Peripheral arterial occlusive disease: Global gene expression analyses suggest a major role for immune and inflammatory responses"</p><p>http://www.biomedcentral.com/1471-2164/9/369</p><p>BMC Genomics 2008;9():369-369.</p><p>Published online 1 Aug 2008</p><p>PMCID:PMC2529314.</p><p></p
Peripheral arterial occlusive disease: Global gene expression analyses suggest a major role for immune and inflammatory responses-7
S illustrated with significantly regulated genes highlighted.<p><b>Copyright information:</b></p><p>Taken from "Peripheral arterial occlusive disease: Global gene expression analyses suggest a major role for immune and inflammatory responses"</p><p>http://www.biomedcentral.com/1471-2164/9/369</p><p>BMC Genomics 2008;9():369-369.</p><p>Published online 1 Aug 2008</p><p>PMCID:PMC2529314.</p><p></p